Home » Topics » Disease categories and therapies » Urology

Urology
RSS

New 5alpha-reductase inhibitors in the pipeline at Kotobuki

March 8, 2000

Merck returns alpha-adrenergic technology rights to Synaptic

March 7, 2000

C5 inhibitor from Alexion granted fast track status for kidney disease

March 2, 2000

Dosing begins in phase II trial of Alprox-TD for erectile dysfunction

Feb. 28, 2000

Nastech's intranasal apomorphine compared to Viagra in phase II pilot trial

Feb. 25, 2000

Synaptic discovers potent and selective human alpha1D-adrenoceptor antagonists

Feb. 24, 2000

Potent and selective alpha1D-adrenoceptor antagonists presented by Abbott

Feb. 18, 2000

Cortex receives notice of allowance for sexual dysfunction patent

Feb. 16, 2000

Preclinical studies support potential new indication for tamsulosin

Feb. 14, 2000

Kissei compounds display excellent beta3-adrenoceptor-stimulating effects

Feb. 11, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...